AIM: The aim of this study was to develop a pharmacogenetic- (PGx) driven approach for a controlled @entity43 (COH) treatment protocol used for in vitro fertilization procedures. The enrolled @entity1 were genotyped for a single nucleotide polymorphism (SNP) @entity23384 , within the @entity23385 . METHODS: Seventy-eight @entity1 , who had previously received at least two COH cycles without positive fertilization with FSH and AMH values <10 mUI/mL and >0.3 ng/mL respectively were enrolled. They were genotyped for @entity23384 and then categorized in high (HR), intermediate (IR), and poor responders (PR). Each subgroup received a tailored FSH treatment of 100, 225, and 400 UI/mL, respectively. The response was evaluated considering differences with previous COH cycle in terms of number of follicles (FR), oocytes (OR), and embryos produced (EMB). RESULTS: With regards to the endpoint considered comparing the non-PGx with the PGx approach, for what regards the FR a statistically significant increase of their numbers was observed with the PGx-tailored approach (HR P<0.0001; IR P=0.00892; PR P=0.0032). Similar statistical significant results were also achieved for OR but only for HR (P<0.0001) and IR (P=0.00169). Last but not least for the EMB (HR P<0.001; IR P=0.00670 and PR P<0.0001) all the different genotype considered achieved a statistical significance. CONCLUSION: This study, although with a limited number of enrolled @entity1 , showed that a FSH treatment with a PGx-driven approach might have the potential to improve COH clinical outcome.

A pharmacogenetic-driven approach for controlled XXXX by FSH treatment.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian hyperstimulation'] @entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity23385 :: ('2492', 'Gene') :: ['FSHR'] @entity23384 :: ('p|SUB|N|680|S', 'ProteinMutation') :: ['N680S']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian hyperstimulation']
